Navigation Links
New Study Finds 1 in 4 Multiple Sclerosis Patients With High Out-of-Pocket Costs Not Filling Prescriptions
Date:6/17/2009

Avoiding medications may adversely affect patient care and increase health care costs

ST. PAUL, Minn., June 17 /PRNewswire/ -- One in four multiple sclerosis (MS) patients are declining to fill their prescriptions likely due to high out-of-pocket costs, according to new research conducted by pharmacy benefits manager Prime Therapeutics (Prime). The study found that patients with an out-of-pocket expense greater than $250 were seven times more likely to decline to fill their prescription than patients with an out-of-pocket cost of $100 or less. The study concluded that this increase in the number of patients who decline to fill their MS specialty prescriptions and do not continue taking the necessary MS medications may adversely affect long term patient care.

According to the study, the majority of individuals had an out-of-pocket expense of $150 or less and their decline to fill rate was 5.8 percent. For individuals with an out-of-pocket expense of greater than $150 the decline to fill rate was 27.0 percent.

"Specialty pharmacy costs are rising and insurers are focusing on ways to best manage costs, including increasing out-of-pocket costs for members," said Patrick Gleason, PharmD, FCCP, BCPS, lead author and Director of Clinical Outcomes Assessment at Prime Therapeutics. "Our research suggests members who pay high out-of-pocket costs are declining to fill their prescription. Patients who aren't taking their medications face serious medical and health complications, which could result in substantial medical or hospitalization expenses for both the patient and health insurer. Health insurers should consider member cost and the impact it has on adherence when designing specialty pharmacy benefits. "

Multiple sclerosis specialty medications (Avonex(R), Rebif(R), Betaseron(R) or Copaxone(R)) have a typical average wholesale price of $2,500 per month supply, $30,000 annually. Due to the potential large member expense for this specialty drug class, Prime designed the study to examine whether an association existed between declining to fill and out-of-pocket expenses. The study considered a member as "declining to fill" whenever there was a reversed claim for a MS specialty medication and no paid claims for that medication during the following 90 days. The study looked at a database of seven million members from eight commercial Blue Cross and Blue Shield plans who presented a new MS medication prescription to be filled at the pharmacy.

Prime Therapeutics LLC is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 14.7 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minn., Prime Therapeutics is collectively owned by 11 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at www.primetherapeutics.com.


'/>"/>
SOURCE Prime Therapeutics LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Study Shows Increases in Working After 65 and Using Commercial Insurance
2. Bariatric Advantage High Protein Meal Replacement Clinical Study Presented at European Congress on Obesity
3. AGH Joins Select Group of Medical Centers in Study of Promising New Technology for Treatment of Heart Failure
4. Study Refutes Depression Gene Finding
5. Providing health insurance for US children would be cheaper than expected, study says
6. Study finds autistics better at problem-solving
7. Cannabis alters human DNA -- new study
8. HPV Vaccine Acceptability Study Announces Results
9. MUHC researcher awarded $500,000 to study pathogenesis of infectious disease
10. HealthLeaders-InterStudy Launches Pharmacy Benefit Evaluator
11. Scientific Study Makes it Possible to Measure Connection Between People
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: